Medtech: if regulatory is blocking your marketing, the problem lies elsewhere

You have a solid product and a committed team. Yet every brochure, every web page, every post stays stuck for weeks between marketing and regulatory. The back-and-forth never ends, sales are waiting for their materials, and the launch slips.

The instinct is to blame regulatory. That is rarely the right diagnosis. Most of the time, the bottleneck lies elsewhere: there is no messaging foundation approved upfront. So every piece of collateral starts from scratch, and so does every regulatory review.

Why every piece gets stuck in review

In medtech, every piece of collateral must go through regulatory before it is released. That is normal and non-negotiable. The problem is how marketing gets there.

Two habits drag the cycles out:

• Numbers first. A scientific culture pushes you to back everything with figures. But every figure you put forward must be supported by a study that proves it. Every figure you add means one more check.
• Form before substance. A fully designed brochure gets produced, then submitted. One rejected phrase, and the whole piece has to be redone.

The result: every piece of collateral becomes a fresh negotiation with regulatory.

From a scientific culture to a commercial company

The urge to put numbers and scientific evidence front and center comes from the very culture of medtech. Founders often have scientific backgrounds and live through their studies. And those studies have real comparative value.

But a medtech company coming to market has to turn into a commercial company to run an effective, consistent go-to-market. That work goes through marketing and product marketing.

Your prospect first needs to understand:

• what your company does;
• what your products do;
• how they fit into their workflows, in the hospital, the lab or elsewhere;
• what changes for each of your personas.

Scientific evidence comes next, as the conversation progresses. It is backed by dedicated content: scientific publications, webinars, conference talks. This is not about giving up on science, but about placing it at the right point in the buyer journey.

Get the foundation approved, not every single piece

The heart of the matter is having, from day one, a messaging that is consistent, unique, simple and strong. That messaging is the outcome of the go-to-market work done upfront:

1. personas and ICP;
2. the positioning platform;
3. the offer hierarchy;
4. the semantic and SEO strategy, built on the positioning platform.

These naturally lead to a brand book, visual and above all semantic, with fixed wording.

This foundation is what you get approved by regulatory. All your language then flows from it. The materials you create afterwards, whether marketing, communications or product marketing, get approved faster because they rest on a sound, shared, already-approved base.

The grey zone: marketing's call

You need to tell apart what falls under the rules themselves from what falls into a grey zone. A grey zone doesn't mean something is forbidden: it reflects a lack of information on the regulatory side.

In that case, marketing should be able to take the lead on the decision, in line with the positioning platform and the product marketing already approved. Without a foundation, that decision can't be defended. With an approved foundation, it becomes a reasoned one.

Approve substance before form

Review time always depends on how responsive the teams are, on both the marketing and regulatory sides. But a clear process between the two smooths the exchanges and prevents mistakes.

The rule is simple: focus first on content and structure, and get that approved. Any visual design comes afterwards, whatever the marketing or product marketing asset.

1. Write the content and structure from the approved foundation.
2. Get that substance approved by regulatory.
3. Only then, start design and adaptations.

One message, several countries

The rules differ from place to place: between the United States and Europe, but also within Europe itself.

The gap between the US and France is striking. In the US, you can compare yourself directly with a competing solution to demonstrate some form of superiority, as long as you can prove it. This approach, familiar from American advertising, extends all the way to medtech. In France, the exercise is far more restricted.

These differences are best handled when building the foundation, rather than piece by piece.

FAQ

Who should have the final say in the grey zone?

Marketing, as long as the decision sits within the framework already approved: the positioning platform and product marketing. What falls under the rules themselves stays with regulatory.

Can you communicate without a clinical study?

Yes, about what your product does, how it fits into your customers' workflows and what it changes for your personas. Any figure you put forward, however, must be backed by a study.

Where should you start to speed up approvals?

With the positioning platform and the offer hierarchy. That is the foundation everything else flows from, including the semantic brand book to get approved.

How Plan B can help

Plan B supports medtech companies on their go-to-market and branding, to lay down this messaging foundation and get it approved upfront. An audit takes stock of your current positioning and of what is slowing down your approvals.